Background: Cytochrome P450s (CYPs) are drug-metabolizing enzymes catalyzing the metabolism
of about 75% of drug in clinical use. CYP2C9 represents 20% CYP proteins in liver cells and is a crucial
member of CYPs superfamily. CYP2C19 metabolizes very important drugs such as antiulcer drug omeprazole,
the antiplatelet drug clopidogrel and anticonvulsant mephenytoin. Single nucleotide polymorphisms (SNPs) of
CYP genes have been associated with unexpected drug reactions and diseases in different populations.
Objective: We examined the associations of CYP2C9*3 (rs1057910) and CYP2C19*3 (rs4986893) with T2D
in Saudi population.
Methods: We used the allele-specific PCR (AS-PCR) and DNA sequencing in 111 cases and 104 controls for
rs1057910, and in 119 cases and 110 controls for rs4986893.
Results: It is indicated that the genotype distribution of rs1057910 in cases and controls were not significantly
different (P=0.0001). The genotypes of rs1057910 were not associated with type 2 diabetes (T2D) (P>0.05).
Whereas the genotype distribution of rs4986893 in cases and controls was significantly different (P=0.049).
The AA genotype of rs4986893 may be associated in increased risk to T2D with OR=17.25 (2.06-143.8),
Conclusion: The CYP2C9*3 (rs1057910) may not be associated with T2D, while CYP2C19*3 (rs4986893) is
probably associated with T2D. These findings need to be validated in follow-up studies with larger sample
sizes and different populations.
Keywords: CytochromeP450s, CYP2C9 , CYP2C19 , gene polymorphisms, diabetes mellitus, drug metabolism, single nucleotide polymorphisms
Rights & PermissionsPrintExport